Drug Trial Radar · NCT00531817
A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis
Last checked: Nov 20, 2026Latest source record: Aug 20, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
619
Actual
Start
Oct 2007
Primary completion
Jun 2009
Study completion Mar 2011
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Sep 19, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This 2-arm study assessed the safety and efficacy of tocilizumab versus placebo, both in combination with disease modifying antirheumatic drugs (DMARDs), in regard to reduction in signs and symptoms, in patients with moderate to severe active rheumatoid arthritis with an inadequate response to DMARDs. Patients were randomized in a ratio of 2:1 to receive either tocilizumab 8 mg/kg intravenously (IV) or placebo IV every 4 weeks. All patients also received stable antirheumatic therapy, including permitted DMARDs. The anticipated time on study treatment was 3-12 months and the target sample size was 500+ individuals.
Conditions
- Rheumatoid Arthritis
Interventions
TocilizumabDrug
Tocilizumab intravenously at a dose of 8 mg/kg over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.
PlaceboDrug
Placebo IV over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.
Permitted DMARDsDrug
As prescribed. The following DMARDs were permitted in this study: methotrexate (MTX), chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These DMARDs could be used alone or in combination, except for the combination of MTX and leflunomide, which was not allowed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients With an Improvement of at Least 50% in American College of Rheumatology (ACR) Score (ACR50) From Baseline at Week 24Time frame: Baseline to Week 24
Locations
157 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Birmingham, Alabama
Site not named
Birmingham, Alabama
Site not named
Montgomery, Alabama
Site not named
Lake Havasu City, Arizona
Site not named
Paradise Valley, Arizona
Site not named
Peoria, Arizona
Site not named
Scottsdale, Arizona
Site not named
Scottsdale, Arizona
Site not named
Jonesboro, Arkansas
Site not named
Beverly Hills, California
Site not named
Escondido, California
Site not named
La Jolla, California
Site not named
Long Beach, California
Site not named
Los Angeles, California
Site not named
Pasadena, California
Site not named
Santa Maria, California
Site not named
Santa Monica, California
Site not named
Upland, California
Site not named
Van Nuys, California
Site not named
Walnut Creek, California
Site not named
Whittier, California
Site not named
Colorado Springs, Colorado
Site not named
Trumbull, Connecticut
Site not named
Washington D.C., District of Columbia
Site not named
Dunedin, Florida
Site not named
Fort Lauderdale, Florida
Site not named
Lake Mary, Florida
Site not named
Melbourne, Florida
Site not named
Miami, Florida
Site not named
Ocala, Florida
Site not named
Orange Park, Florida
Site not named
Orlando, Florida
Site not named
Palm Harbor, Florida
Site not named
Plantation, Florida
Site not named
Sarasota, Florida
Site not named
Tamarac, Florida
Site not named
Tampa, Florida
Site not named
Atlanta, Georgia
Site not named
Blue Ridge, Georgia
Showing 40 of 157 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.